# BML Capital Management, LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1616824. Source: https://holderbook.com/funds/1616824-bml-capital-management-llc/

- Reported value: $176.1M
- Positions: 18
- Weight of the ten largest: 93.3%
- Filed: 2026-08-07

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ACLARIS THERAPEUTICS INC | [ACRS](https://holderbook.com/stocks/ACRS/) | $63.3M | 11,975,000 | 36.0% | 11 |
| ATEA PHARMACEUTICALS INC | [AVIR](https://holderbook.com/stocks/AVIR/) | $32.3M | 6,952,330 | 18.4% | 13 |
| Engene Therapeutics Inc | [ENGN](https://holderbook.com/stocks/ENGN/) | $11.5M | 6,669,908 | 6.6% | 1 |
| KRAFT HEINZ CO | [KHC](https://holderbook.com/stocks/KHC/) | $11.0M | 465,000 | 6.2% | 2 |
| OUTSET MED INC | [OM](https://holderbook.com/stocks/OM/) | $10.9M | 2,519,701 | 6.2% | 3 |
| CARMAX INC | [KMX](https://holderbook.com/stocks/KMX/) | $9.1M | 172,500 | 5.2% | 3 |
| TILLYS INC | [TLYS](https://holderbook.com/stocks/TLYS/) | $9.0M | 2,150,000 | 5.1% | 2 |
| PMV PHARMACEUTICALS INC | [PMVP](https://holderbook.com/stocks/PMVP/) | $7.1M | 5,330,000 | 4.1% | 10 |
| INSTIL BIO INC | [TIL](https://holderbook.com/stocks/TIL/) | $5.0M | 645,600 | 2.8% | 10 |
| TARGET CORP | [TGT](https://holderbook.com/stocks/TGT/) | $4.9M | 37,500 | 2.8% | 4 |
| ORAMED PHARMACEUTICALS INC | [ORMP](https://holderbook.com/stocks/ORMP/) | $4.2M | 866,269 | 2.4% | 14 |
| JANUX THERAPEUTICS INC | [JANX](https://holderbook.com/stocks/JANX/) | $2.4M | 154,961 | 1.4% | 2 |
| PLIANT THERAPEUTICS INC | [PLRX](https://holderbook.com/stocks/PLRX/) | $1.8M | 1,546,137 | 1.0% | 3 |
| CONNECT BIOPHARMA HLDGS LTD | [CNTB](https://holderbook.com/stocks/CNTB/) | $1.4M | 573,287 | 0.8% | 4 |
| IMAGENEBIO INC | [IMA](https://holderbook.com/stocks/IMA/) | $1.2M | 200,730 | 0.7% | 4 |
| WALMART INC | [WMT](https://holderbook.com/stocks/WMT/) | $386.1K | 0 | 0.2% | 4 |
| CORE SCIENTIFIC INC NEW | [CORZ](https://holderbook.com/stocks/CORZ/) | $298.0K | 0 | 0.2% | 1 |
| TESLA INC | [TSLA](https://holderbook.com/stocks/TSLA/) | $270.0K | 0 | 0.2% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +16.7% | +14.8% | +1.9% | 97% |
| Q1 2026 | +23.1% | -4.6% | +27.7% | 100% |
| Q4 2025 | +29.4% | +2.4% | +27.1% | 84% |
| Q3 2025 | +4.4% | +7.8% | -3.4% | 92% |
| Q2 2025 | +6.5% | +10.5% | -3.9% | 100% |
| Q1 2025 | -17.3% | -4.6% | -12.7% | 100% |
| Q4 2024 | +4.0% | +2.1% | +1.8% | 96% |
| Q3 2024 | +20.6% | +5.4% | +15.2% | 99% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $176.1M | 18 |
| Q1 2026 | $155.8M | 16 |
| Q4 2025 | $115.7M | 16 |
| Q3 2025 | $109.2M | 19 |
| Q2 2025 | $132.2M | 24 |
| Q1 2025 | $123.6M | 26 |
| Q4 2024 | $161.0M | 25 |
| Q3 2024 | $169.9M | 29 |
| Q2 2024 | $140.1M | 28 |
| Q1 2024 | $151.7M | 32 |
| Q4 2023 | $132.0M | 35 |
| Q3 2023 | $108.9M | 26 |